Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Copolymer 1: from basic research to clinical application

D Teitelbaum1, R Arnon, M Sela

  • 1Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Cellular and Molecular Life Sciences : CMLS
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy.

Multiple sclerosis (Houndmills, Basingstoke, England)·2003
Same author

Technique for fabrication of splint preventing postsurgical restenosis in choanal atresia.

The Journal of prosthetic dentistry·2003
Same author

Harnessing the osseointegration principle for anchorage of fingernail prostheses.

Hand clinics·2003
Same author

[The use of Dental D (polyacetal resin) as an alternative for chrome-cobalt removable partial denture: a case report].

Refu'at ha-peh veha-shinayim (1993)·2002
Same author

Metastatic hypernephroma to the head and neck: unusual case reports and review of the literature.

The Journal of otolaryngology·2002
Same author

The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.

Proceedings of the National Academy of Sciences of the United States of America·2001
Same journal

Single-Cell dissection of fibrodysplasia ossificans progressiva identifies SPP1 as a mediator of macrophage-fibroadipogenic progenitors crosstalk.

Cellular and molecular life sciences : CMLS·2026
Same journal

Ablation of the renal tubular gluconeogenic enzyme PCK1 drives AKI-to-CKD transition by negatively regulating the TGF-β/Smad3 signaling pathway.

Cellular and molecular life sciences : CMLS·2026
Same journal

LncRNA modulates Dpp-mediated wing development to influence flight in Aedes aegypti.

Cellular and molecular life sciences : CMLS·2026
Same journal

TROP2 promotes bone metastasis of colorectal cancer through interaction with the fibronectin-integrin axis.

Cellular and molecular life sciences : CMLS·2026
Same journal

PRMT5-Cacna1d axis maintains calcium homeostasis to regulate postnatal motor development in mice.

Cellular and molecular life sciences : CMLS·2026
Same journal

Advances and clinical potential of epigenome editing.

Cellular and molecular life sciences : CMLS·2026
See all related articles

Copolymer 1 (Cop-1) effectively suppresses experimental allergic encephalomyelitis (EAE) and shows promise in slowing multiple sclerosis (MS) progression. Its mechanism involves immune modulation, offering a targeted approach with reduced long-term risks.

Area of Science:

  • Neuroimmunology
  • Immunotherapy

Background:

  • Experimental allergic encephalomyelitis (EAE) serves as a model for multiple sclerosis (MS).
  • Copolymer 1 (Cop-1) is a synthetic amino acid polymer with demonstrated efficacy in EAE suppression.

Purpose of the Study:

  • To elucidate the mechanism of action for Cop-1 in EAE and MS.
  • To evaluate the therapeutic potential of Cop-1 in autoimmune neurological conditions.

Main Methods:

  • In vivo and in vitro studies were conducted to investigate Cop-1's immunomodulatory effects.
  • Clinical trials (Phase III) assessed Cop-1's impact on disability progression and relapse rates in MS patients.

Main Results:

  • Cop-1 demonstrated a general suppressive effect in EAE across different species and induction methods.

Related Experiment Videos

  • Phase III trials indicated that Cop-1 slows disability progression and reduces relapse rates in relapsing-remitting MS.
  • Mechanism involves Cop-1 binding to MHC class II molecules, competing with myelin antigens, and inducing Th2-type suppressor cells.

    • Conclusions:

    • Cop-1 is an effective immunomodulatory agent for EAE and shows therapeutic benefits in MS.
    • The antigen-specific mechanism of Cop-1 offers a potentially safer alternative to broad immunosuppression.
    • Cop-1's ability to induce suppressor cells suggests a favorable long-term safety profile for immune system integrity.